Our approach goes beyond just writing a prescription
The appetite-control aisle has explodedfiber capsules, thermogenic pills, herbal extracts, and now products claiming to influence GLP-1
Clinical Eligibility (The BMI Rule) According to FDA and ADA 2026 standards, you should consider Semaglutide if you meet one of these two criteria: BMI of 30 or greater: Classified as obesity
Amgens MariTidewhich combines a GLP-1 agonist with a GIP antagonistis also being tested as a monthly injection, with several Phase III trials in the works.
Why This New Approach Works : The combination of telehealth and advanced treatment options is helping more people take control of their health with confidence
Our approach combines medical evaluation, nutrition guidance, behavioral support, and when appropriate, medication options to help you achieve and maintain your goals